Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.
Lombardi F, Belmonti S, Quiros-Roldan E, Latini A, Castagna A, D'Ettorre G, Gagliardini R, Fabbiani M, Cauda R, De Luca A, Di Giambenedetto S; AtLaS-M Study Group. Lombardi F, et al. Among authors: de luca a. J Antimicrob Chemother. 2017 Jul 1;72(7):2055-2059. doi: 10.1093/jac/dkx068. J Antimicrob Chemother. 2017. PMID: 28333353 Clinical Trial.
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L, D'Avino A, Mondi A, Cingolani A, Tamburrini E, Murri R, Navarra P, Cauda R, De Luca A. Di Giambenedetto S, et al. Among authors: de luca a. J Antimicrob Chemother. 2013 Jun;68(6):1364-72. doi: 10.1093/jac/dkt007. Epub 2013 Jan 30. J Antimicrob Chemother. 2013. PMID: 23372058
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy.
Meini G, Rossetti B, Bianco C, Ceccherini-Silberstein F, Di Giambenedetto S, Sighinolfi L, Monno L, Castagna A, Rozera G, D'Arminio Monforte A, Zazzi M, De Luca A; ICONA Foundation Group. Meini G, et al. Among authors: de luca a. J Antimicrob Chemother. 2014 Mar;69(3):735-41. doi: 10.1093/jac/dkt426. Epub 2013 Oct 23. J Antimicrob Chemother. 2014. PMID: 24155059 Free PMC article.
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
Fabbiani M, Mondi A, Colafigli M, D'Ettorre G, Paoletti F, D'Avino A, Ciccarelli N, Sidella L, Murri R, Fortuna S, Vullo V, Cauda R, De Luca A, Di Giambenedetto S. Fabbiani M, et al. Among authors: de luca a. Scand J Infect Dis. 2014 Jan;46(1):34-45. doi: 10.3109/00365548.2013.840920. Epub 2013 Oct 28. Scand J Infect Dis. 2014. PMID: 24161018 Clinical Trial.
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure.
Rozera G, Abbate I, Giombini E, Castagna A, De Luca A, Ceccherini-Silberstein F, Cozzi Lepri A, Cassola G, Torti C, d'Arminio Monforte A, Ippolito G, Capobianchi MR; ICONA Foundation Group. Rozera G, et al. Among authors: de luca a. J Antimicrob Chemother. 2014 Nov;69(11):3085-94. doi: 10.1093/jac/dku255. Epub 2014 Jul 10. J Antimicrob Chemother. 2014. PMID: 25015667
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.
Fabbiani M, Di Giambenedetto S, Quiros-Roldan E, Latini A, Vullo V, Antinori A, Castagna A, Orofino G, Francisci D, Grilli E, Madeddu G, Grima P, Rusconi S, Del Pin B, Mondi A, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R. Fabbiani M, et al. Among authors: de luca a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19808. doi: 10.7448/IAS.17.4.19808. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397552 Free PMC article.
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients.
Gagliardini R, Fabbiani M, Colafigli M, D'Avino A, Mondi A, Borghetti A, Lamonica S, Cauda R, De Luca A, Di Giambenedetto S. Gagliardini R, et al. Among authors: de luca a. J Chemother. 2017 Oct;29(5):299-307. doi: 10.1080/1120009X.2016.1269040. Epub 2016 Dec 26. J Chemother. 2017. PMID: 28019192
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).
Di Giambenedetto S, Fabbiani M, Quiros Roldan E, Latini A, D'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Di Pietro M, Mondi A, Ciccarelli N, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R; Atlas-M Study Group. Di Giambenedetto S, et al. Among authors: de luca a. J Antimicrob Chemother. 2017 Apr 1;72(4):1163-1171. doi: 10.1093/jac/dkw557. J Antimicrob Chemother. 2017. PMID: 28093483 Clinical Trial.
2,182 results